At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 189 enrolled
Drug / intervention
ACZ885 +1 moredrug
Likely dose
ACZ885 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT
In Brief
A Phase 2 clinical trial evaluating ACZ885 and Placebo for Diabetes Mellitus, Type 2 and 2 related conditions. Completed, enrolled 189 participants across 9 sites in 5 countries.
Detailed Summary
This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Germany, Israel, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartDec 2009
Primary CompletionFeb 2014
TodayJul 2026
First PostedOct 16, 2009
Enrollment StartDec 1, 2009
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 16.7 years ago
Interventions
ACZ885drug
ACZ885 150 mg was administered subcutaneously once a month for 12 months.
Placebodrug
Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.